BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns negative
Q1 FY2026 Accumulated OCI was -$981K, compared with $191K a year earlier.
Context
- Accumulated OCI amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -613.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 16K USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accumulated OCI vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -613.6% is the 6th highest of 8, against a peer median of -276.5%.
- Accumulated OCI amounts to 0.2% of total assets for BBOT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 30.1M CHF | +1639.0% | +134.1% | 12.4% | |
| Mar 2026 | $8K USD | -42.9% | — | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | -$146K USD | -190.7% | — | 0.0% | |
| Aug 2026 | -$210K USD | -276.5% | — | 0.0% | |
| Jun 2026 | -$872K USD | -438.0% | — | 0.1% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | -$981K USD | -613.6% | — | 0.2% |
SEPNSepterna, Inc. | Sep 2026 | -$2.05M USD | -645.3% | — | 0.3% |
| Sep 2026 | -$4.51M USD | -3825.7% | — | 0.4% | |
| Peer median (excluding BBOT) | — | -276.5% | +134.1% | 0.0% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.